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The best new therapeutic entity in the world is of little value without an appropriate 
delivery system. Tablet delivery systems can range from simple immediate release 
formulations to complex extended or modified release dosage forms. The most 
important role of drug delivery system is to get the drug delivered to the site of action 
in sufficient amount and at the appropriate rate; however it must also meet a number 
of other essential criteria. These include physical and chemical stability, ability to be 
economically mass produced in a manner that assures the proper amount of drug in 
each and every dosage form and in each batch produced and as far as possible patient 
acceptability the drug and the delivery systems cannot be separated.
1-2 
 
The general design criteria for tablet are given below
4 
1.) Optimal drug dissolution and hence availability of drug from dosage form 
for absorption consistent with internal use (i.e. immediate or extended 
release) 
2.) Accuracy and uniformity of drug content 
3.) Stability, including the stability of the substance, the overall tablet 
formulation, disintegration and the rate and extent of drug dissolution from 
the tablet for an extended period. 
4.) Patient acceptability: as much as possible, the finished product should 
have an attractive appearance, including color, size, taste etc. as 
applicable, in order to maximize patent acceptability and encourage 
compliance with prescribed dosing regimen . 
5.) Manufacturability: The formulation design should allow for the efficient, 
cost effective practical production of the required batches. 
SOLID DOSAGE FORMS
2,3
 
Solid dosage forms are widely prevalent due to their age-old application.  Especially, 
oral solid formulations hold a high potential as they serve to be most convenient for 
the administration of drugs.  These have been developed into a wide range of 
formulations from conventional dosage forms for immediate release of the drug to 
controlled release dosage forms for the constant rate of drug release.  Oral route is the 
most convenient and commonly used method of drug delivery.  More than 50% of 
drug delivery systems available in the market are oral drug delivery systems. They 
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offer convenience and ease of administration, greater flexibility in dosage form design 
and ease of production and low cost.  Pharmaceutical oral solid dosage forms have 
been used widely for decades mainly due to their convenience of administration and 
their suitability for delivery of drugs for systemic effects.  The most commonly used 
pharmaceutical solid dosage forms today include granules, pellets, tablets and 
capsules. 
 
TABLET 
 Definition:
1
  
Tablets are tamperproof solid unit dosage forms containing medicament or mixture of 
medicaments and excipients compressed or moulded into solid cylindrical shape 
having either flat or convex surfaces. 
 
Advantages of the Tablets
1
 
 They are unit dosage form, and they offer greatest capabilities of all oral dosage 
forms for the greatest dosage precision and the least content variability. 
 Their cost is lowest of all the dosage forms. 
 They are the lightest and most compact of all the dosage forms. 
 They are in general the easiest and cheapest to package and ship of all oral dosage 
forms. 
 They may provide the greatest ease of swallowing with the least tendency for   
“hang-up” above the stomach, especially when coated, provided that tablet 
disintegration is not excessively rapid. 
 They lend themselves to certain special release profile products, such as enteric or 
delayed release products. 
 They are better suited to large-scale production than the other unit oral forms. 
 They have the best-combined properties of chemical, mechanical and 
microbiological stability of all the oral forms. 
Disadvantages of the Tablets
1 
 Some drugs resist compression into dense particles, owing to their amorphous 
nature or flocculent, low-density character. 
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 Drugs with poor wetting, slow dissolution properties, intermediate to large 
dosages, optimum absorption high in the GIT, or any combination of these 
features may be difficult or impossible to formulate and manufacture as a tablet. 
 Bitter tasting drugs with an objectionable odor, or drugs that are sensitive to 
oxygen or atmospheric moisture may require encapsulation or entrapment prior to 
compression. 
 
Types and classes of Tablets
4
 
(A) Oral tablet for ingestion 
1. Compressed tablets 
2. Multiple compressed tablets 
3. Delayed action tablets 
4. Sugar coated 
5. Film coated tablets 
6. Chewable tablets 
 
(B) Tablet used in oral cavity 
1. Buccal tablets 
2. Sublingual tablets 
3. Troches and Lozenges 
4. Dental cones 
 
(C) Tablet administered by other routes 
1. Implantation tablets 
2. Vaginal tablets 
 
(D) Tablets used to prepare solution 
1. Effervescent tablets 
2. Dispensing tablets 
3. Hypodermic tablets 
4. Tablet triturates 
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OPERATIONS INVOLVED IN TABLET MANUFACTURING:
5 
The manufacture of oral solid dosage forms such as tablets is a complex multi-stage 
process under which the starting materials change their physical characteristics a 
number of times before the final dosage form is produced. 
The following operations are involved in tablet manufacturing: 
 Dispensing 
 Sifting 
 Dry mixing 
 Granulation 
 Drying 
 Milling 
 Blending 
 Compression 
 Coating 
 Packing 
 
    . DISPENSING:  
  Dispensing is the first step in any pharmaceutical manufacturing process. 
Dispensing is one of the most critical steps in pharmaceutical manufacturing; 
as during this step, the weight of each ingredient in the mixture is determined 
according to dose. 
 Dispensing can be done by purely manual by hand scooping from primary 
containers and weighing each ingredient by hand on a weigh scale on 
mechanical devices according to BPR specification. 
 Issues like weighing accuracy, dusting control (laminar air flow booths, glove 
boxes), during manual handling lot control of each ingredient, material 
movement into and out of dispensary should be considered during dispensing. 
 There should be no due for calibration of the balance and zero error must be 
ensured in the balance. 
 Ensure the expiry date of XXX is later than that of the batch expiry date and 
retest date is older than day of dispensing. 
 Ensure all the materials are issued as per BPR. 
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  SIFTING: 
Size plays an important role in the homogeneity of the final product. When 
large    differences exist between the active ingredient   and excipients mutual 
sieving (demixing) effects can occur making thorough mixing difficult during the 
subsequent processing steps. 
Size can also be a factor in the stability. Fine materials are relatively more 
open to  attack form atmospheric oxygen, heat, light, humidity and interacting 
excipients than  coarse materials. Because of these significant roles it is important 
to decide on a desired size   range, and hence to maintain and control it. 
    Factors to be considered during sifting: 
 Check and record the temperature and relative humidity in process area. 
Temperature should be 25±2º
c
 and RH 45±5%. 
 Check and ensure visually all the equipments and equipment parts are 
cleaned, record remarks if any. 
 Check and record the integrity of the sieves before and after sifting 
through out the processing activity. 
 
MIXING: 
Mixing is defined as the process that tends to result in the randomization of       
dissimilar particles within a system. Dry mixing is generally carried out in a Rapid 
Mixer Granulator. Dry mixing involves the mixing of ingredients before adding the 
granulation or binder solution. 
GRANULATION:
2 
  Granulation  is  a process  of  size  enlargement  whereby  small  particles    
are  gathered  into  larger aggregates  in  which  the  original  particles  can  still  be  
identified. Granulation usually refers  to  processes where agglomerates  with  sizes  
ranging  from  0.1  to  2.0  mm  are  produced.   
The objectives for granulation are: 
 improve the flow properties of the mix 
 uniformity of the dose 
 prevent segregation of the ingredients 
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 reduce dust during handling 
Materials intended for compaction into tablet must possess two characteristics- 
Fluidity-Good flow properties are essential for the transport of the material through 
the hopper into and through the feed frame & into the dies. The ideal physical form 
for this purpose is spheres , since these offer minimum contact surfaces between 
themselves & with the walls of the machine parts. 
Compressibility-It is the property of forming stable, compact mass when pressure is 
applied. 
Hence granulation is a vital step in tablet manufacturing. 
Granulation techniques can be broadly classified into three types.  
 Wet granulation 
 Dry granulation 
 Direct compaction 
Wet granulation 
           When powders are very fine, fluffy, will not stay blended, or will not 
compress, then they must be granulated, it means that the required quantity of powder 
physically will not fit into the die cavity on the tablet press. The volume of fill (bulk 
density) is greater than that which is mechanically allowed. 
Wet granulation, the process of adding a liquid solution to powders, is one of 
the most common ways to granulate where the liquid solution/suspension can be 
either aqueous based or non aqueous based. . Water mixed into the powders can form 
bonds between powder particles that are strong enough to lock them together. 
However, once the water dries, the powders may fall apart. Therefore, water may not 
be strong enough to create and hold a bond. In such instances, a liquid solution that 
includes a binder (pharmaceutical glue) is required. Once the solvent has been dried 
and the powders have formed a more densely held mass, then the mass is milled. This 
process results in the formation of granules. 
Types of Binders 
Some binders, called wet binders, only work when added as a solution. Dry 
binders are preprocessed powders that when mixed with other powders help bind the 
ingredients together. Binders that can be used wet or dry are also available.  
Eg: starch, starch derivatives, cellulose derivatives, alginate derivatives, sorbitol, 
povidone (PVP) etc. 
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Wet granulation offers a wide range of capabilities for forming granules, from 
the production of light granules to the production of very dense granules. More than 
70% of the global industry‟s granulations are made using this method. 
Important steps involved in the wet granulation: 
 Mixing of the drug(s) and excipients. 
 Preparation of binder solution. 
 Mixing of binder solution with powder mixture to form wet mass. 
 coarse screening of wet mass using a suitable sieve.(#6-#12) 
 Drying of moist granules. 
 screening of dry granules through a suitable sieve(#14-#20) 
 Mixing of screened granules with disintegrants, glidant and lubricant. 
Preparing the damp mass: 
A liquid binder is added to the powder mixture to facilitate the adhesion of the 
powder particles. a good binder results in appropriate tablet hardness and does not 
negatively impact on the release of the drug from the tablet. 
Determining the End point of granulation: 
A rough way of determining the end point to press a portion of the mass in the 
palm of the hand, if the ball crumbles under moderate pressure ;the mixture is ready 
for the next stage in processing , which is wet screening.  
Relation between power consumption and granule formation: 
The energy consumption by wet  granulation (i.e.; the cumulative power 
consumption.)is converted completely into heat. The particles get heated up as 
coalescence of agglomerates becomes significant. Because of high agglomerates 
deformability the energy consumption will increase accordingly. 
The power used by the mixer increases as the powder mass becomes 
increasingly wet. Power usage is often reflected in the readings of an ammeter or 
wattmeter mounted on the equipment and may be useful in helping to identify the 
proper end point for the wet granulation process. 
Care must be exercised not to over wet or under wet the powder. Over wetting 
can result in granules that are too hard for proper tabletting. 
Under wetting can result in tablets that are too soft and may tend to crumble. 
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Screening the damp mass into granules: 
The wet mass is passed through a screen (usually no. # 6 or 8 mesh) to prepare 
the granules. This may be done by hand or by special equipment which prepares the 
granules by extrusion through perforations in the apparatus. The resultant granules are 
spread evenly on large pieces of paper in shallow trays and dried. 
Dry granulation 
The dry granulation process is used to form granules without using a liquid 
solution because the product to be granulated may be sensitive to moisture and heat. 
Forming granules without moisture requires compacting and densifying the powders.  
Dry granulation can be conducted on a tablet press using slugging tooling or 
on a roller compactor commonly referred to as a chilsonator. When a tablet press is 
used for dry granulation, the powders may not possess enough natural flow to feed the 
product uniformly into the die cavity, resulting in varying degrees of densification. 
The roller compactor uses an auger feed system that will consistently deliver powder 
uniformly between two pressure rollers. 
           The powders are compacted into a ribbon or small pellets between these rollers 
and milled through a low-shear mill. When the product is compacted properly, then it 
can be passed through a mill and final blend before tablet compression. 
 Material feed rates are critical for attaining the final objective. The process 
may require repeated compaction steps to attain the proper granular end point. If fines 
are not removed or reprocessed, then the batch may contain too many of them, a 
situation that can contribute to capping, laminating, weight, and hardness problems on 
the tablet press. Roller compacting the complete formula is not usually necessary. The 
object is to  densify powders and form granules of the products in the formula that 
must be compacted, mill the granules, and then blend them back in with the rest of the 
formula‟s ingredients. Most dry-granulated products do not have problems with 
picking and sticking because moisture is not present. 
When products are dry granulated, the process times are often reduced and 
equipment requirements are streamlined; therefore, the cost is reduced. However, dry 
granulation often produces a higher percentage of fines or no compacted products, 
which can lead to compromised tablet quality or yield problems if the product is not 
compacted correctly. 
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Direct compaction 
         The drug & all the excipients are blended together and then compressed. This 
technique is applicable to those substances which can be directly compressed (eg. 
sodium chloride, sodium bromide & potassium bromide). 
DRYING:
5
  
 Drying is defined as the removal of a liquid from a material by the application of 
heat and is accomplished by the transfer of a liquid from a surface into an unsaturated 
vapor phase. 
Steps followed in drying: 
  Check and ensure the integrity of the FBD bag. 
  Initially dry the wet granules with air for 10 minutes, till the odor of IPA is 
eliminated. 
  Dry the granules as per BPR instructions. 
  Check the LOD of granules. 
  Check and ensure the dried granules are not stored above 25ºC before the 
milling is started. 
  Check the integrity of the sieves before and after sieving. 
  Collect the weight of sifted and dried granules. 
Sizing the Granulation by dry screening: 
After drying, the granules are passed through a screen of a smaller mesh than 
used to prepare the original granulations. The degree to which the granules are 
reduced depends upon the size of the punches to be used. In general, the smaller the 
tablet to be produced, the smaller are the granules used. Screens from 12 to 20 mesh 
size are generally used for this purpose. Sizing of the granules is necessary so that the 
die cavities for the free flowing granulation. Voids or air spaces left in too large 
granulation would result in the production of uneven tablets. 
Blending and Lubrication: 
After dry screening, a dry lubricant is coated over the granules by blending the 
lubricant with the granules. The powder/granules blending are involved at stage of 
pregranulation and/or post granulation stage of tablet manufacturing. Each process of 
mixing has optimum mixing time and so prolonged mixing may result in an undesired 
product.  So, the optimum mixing time and mixing speed are to be evaluated.  
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Blending step prior to compression is normally achieved in a simple tumble blender.  
The blender may be mixed blender into which the powder are charged, blended and 
discharged.  In special cases of mixing a lubricant, over mixing should be particularly 
monitored. 
The various blenders used include Double cone blender, ‟V‟ blender, Octagonal 
blender, Container blender, Tumbling blender, Agitated powder blender, etc. 
Lubricants contribute to the preparation of compressed tablets in several ways. 
 They improve flow of the granulation in the hopper to the die cavity. 
 They prevent the adhesion of the tablet formulation to the punches and dies 
during compression. 
 They reduce friction between the tablet and the die wall during the tablet‟s 
ejection from the tablet machine. 
 They give sheen to the finished tablets. 
 
Factors to be considered in Granulation: 
MIXING TIME:  
The mixing time also determines quality of the granules. 
If wet mixing time is high the tablet may fail the dissolution test since drug release 
from hard granules is late. 
 
IMPELLER MOVEMENT  
Adhesion of wetted mass to the vessel is less if impeller movement is helical. This 
gives a narrower granule size and few lumps. 
 
Factors to be considered during drying: 
 Loss on Drying: 
LOD, is an expression of moisture content on a wet- weight basis, which is 
calculated as 
                      % LOD = wt. of water in sample        X   100                                                                                               
                             Total wt. of wet sample 
          The moisture in a solid can be expressed on a wet – weight or dry – weight 
basis. On wet – weight basis, the water content of a material is calculated as the 
Chapter 1                                                                                             INTRODUCTION 
Dept of Pharmaceutics                                J.K.K.Nattraja College of Pharmacy     11 
  
 
 
percentage of the weight of the wet solid, whereas on dry – weight basis, the water is 
expressed as a percentage of the weight of the dry solid. 
Moisture Content: 
 Measurement of the moisture in wet a solid is calculated on a dry – weight basis. 
                     % MC = wt of water in sample      X   100 
            Wt. of dry sample 
Milling 
Milling is the mechanical process of reducing the particle size of solids. 
Milling equipment is usually classified as 
COARSE             # 20 mesh  
INTERMEDIATE                        #   20 -200 mesh 
FINE MILLING                                           < # 200 mesh 
 
Pharmaceutical Applications: 
 The control of particle size and specific surface affects the therapeutic efficiency 
of medical compounds. 
 The drying of wet masses may be facilitated by milling, which increases the 
surface area and reduces the distance, the moisture must travel within the particle 
to reach the outer surface. 
 Milling enables the free flow of powder to produce tablets of uniform weight. 
 The mixing and blending of several solid ingredients of a pharmaceutical is easier 
and more uniform if the ingredients are approximately of the same size. 
 
TABLET COMPRESSION:
2 
After the preparation of granules (in case of wet granulation) or slugs (in case 
of dry granulation) or mixing of ingredients (in case of direct compression), they are 
compressed to the final product. 
There are a number of types of tablet presses or tableting machines, each 
varying in productivity but similar in basic function and operation. They all compress 
a tablet formulation within a steel die cavity by the pressure exerted by the movement 
of two steel punches, lower punch and an upper punch. It „squeezes‟ the ingredient 
into the required tablet shape with extreme precision. It can make the tablet in many 
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shapes, although they are usually round or oval.  Also, it can press the name of the 
manufacturer or the product into the top of the tablet. 
The operation of a single punch describes the basic mechanical process. 
 
Stages occurring during compression:- 
 Stage1:  Top punch is withdrawn from the die by the upper cam .bottom punch 
is low in the die so the powder falls in through the hole and fills the die. 
 Stage 2:  Bottom punch moves up to adjust the powder weight it raises and 
expels some powder. 
 Stage 3:  Top punch is driven into the die by upper cam. Bottom punch is 
raised by lower cam. Both punch heads pass between heavy rollers to 
compress the powder ie. compression & consolidation takes place. 
 Stage 4:   The upper cam withdraws top punch & lower punch is pushed up 
and expels the tablet ie. ejection takes place. Tablet is removed from the die 
surface-by-surface plate. 
 Stage 5:  Return to stage 1. 
 Rotary tablet machines equipped with multiple punches operate through the 
continuous rotating movement of the punches. 
 
Factors to be considered during compression: 
 Check and ensure the temperature and relative density humidity of the 
compression room is not more than 25ºC and RH not more than 50%. 
 Check and ensure the compression machine is cleaned as per BPR. 
 Collect 40 tablets and inspect for appearance, weight, thickness, friability and 
hardness every 1-hour and every break as per BPR. 
 Tablet weight variation, hardness & thickness should be within the limit as per 
BPR. 
 Collect 40 by “Bracketting” i.e., by increasing this speed of the compression 
machine from the target speed and by reducing the speed by 4 rpm. 
 Collect 10 tablets during initial, middle and end of the compression process 
and conduct analysis for content uniformity and assay. 
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TABLET COATING:   
 Tablet coating is the application of coating composition to moving bed of 
tablets & concurrent use of heated air to facilitate evaporation of solvent. 
 
FILM COATING: 
Film coating is deposition of thin film of polymer surrounding the tablet core. 
Conventional pan equipments may be used but now-a-days more sophisticated 
equipments are employed to have a high degree of automation and quality coating. 
The polymer is solubilised in solvent & other additives like plasticizers and pigments 
are added. Resulting solution is sprayed onto a rotated tablet bed. The drying 
conditions cause removal of the solvent, giving thin deposition of coating material 
around each tablet. 
 
Factors to be considered during coating process: 
 Check and ensure the coating pan and other equipments are cleaned as per 
BPR. 
 Check and ensure that the speed of the coating pan, gun to bed distance, inlet 
and exhaust air temperature, spray rate, spray type, number of guns, 
temperature of the coating solution are as per BPR instruction. 
 After coating is completed, samples are collected for dissolution testing and 
weight variation. 
Coating parameters to be considered: 
 Spray gun model 
 Pan load (kg) 
 Pan speed (rpm) 
 Spray procedure 
 Spray rate (g/min) 
 No. of spray guns 
 Distance between spray guns (cm)) 
 Distance between spray gun & tablet bed 
 Main inlet pressure (kg/cm²) 
 Atomization pressure (kg/cm²) 
 Inlet air temperature (ºC) 
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 Tablet bed temperature (ºC) 
  Position of dampers - inlet 
 - Outlet 
                   - % inlet / % outlet  
 Quantity of coating suspension in the liquid vessel (kg/ltr) 
 Average weight preheated core tablets (mg) 
 
PROCESS VARIABLES DURING FILM COATING 
The variables to be controlled during pan spray film coating processes are: 
1. Pan variables: 
 Pan design/baffling 
 Speed 
 Pan load 
2. Process- Air 
 Air quality 
 Temperature 
 Airflow rate/volume/balance 
3. Spray variables 
 Spray rate 
 Degree of atomization 
 Spray pattern 
 Nozzle to bed distance 
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LITERATURE REVIEW 
Mahesh Kumar S et al; In Vitro and In Vivo Studies on HPMC-K-100 M 
Matrices Containing Loxoprofen Sodium; Drug Delivery, Volume 14, Issue 3 
March 2007 , pages 163 – 169 
Controlled release (CR) matrix tablets of loxoprofen sodium were prepared by 
wet granulation using hydroxypropyl methyl cellulose (HPMC-K-100 CR) as the 
hydrophilic rate controlling polymer. The effect of the concentration of the polymer 
and different fillers on the in vitro drug release rate was studied. The studies indicated 
that the drug release can be modulated by varying the concentration of the polymer 
and the fillers. An optimized formulation subjected to accelerated stability studies for 
3 months revealed that the developed CR tablets are stable. A complete cross-over 
bioavailability study of the optimized formulation of the developed CR tablets and 
marketed immediate release tablets was performed in 6 healthy male volunteers. The 
extent of absorption of drug from the CR tablets was significantly higher than that for 
the marketed loxoprofen sodium tablet due to lower elimination rate and longer half-
life.  
 
Dahl T et al; Effects of various granulating systems on the bioavailability of 
loxoprofen sodium from polymeric matrix tablets; Journal of Pharmaceutical 
Sciences, Volume 79, Issue 5,Sep 2006, Pages 389 – 392. 
Loxoprofen sodium and a cellulose ether derivative were granulated with 
either water or a poly(meth)acrylic acid ester copolymer aqueous dispersion to make 
three controlled-release matrix dosage forms. The different polymeric matrix systems 
contained hydroxypropyl methylcellulose (formulation A), hydroxypropylcellulose: 
poly-(meth)acrylic acid ester copolymer (formulation B), and hydroxypropyl 
methylcellulose:poly(meth)acrylic acid ester copolymer (formulation C). All three 
hydrophilic matrix tablets demonstrated identical in vitro dissolution rates. The three 
controlled-release formulations were compared with a marketed immediate-release 
loxoprofen sodium dosage form (formulation D) in a single-dose crossover study in 
six healthy volunteers. 
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Piera Di Martino et al; Physico-chemical and technological properties of sodium 
loxoprofen granules prepared in a high-shear mixer-granulator; Journal of 
Pharmaceutical Sciences, Volume 97, Issue 12, Apr 2008, Pages  5263-5273. 
  In the present work, authors produced tablets of anhydrous sodium loxoprofen 
by wet granulation using a high-shear mixer-granulator. Drug hydrated to the 
tetrahydrated form, as observed by X-ray powder diffractometry. 
 
Young-soo Kim et al; Solubility and prediction of the heat of solution of sodium 
loxoprofen in aqueous solutions; Journal of Pharmaceutical Sciences, Volume 94, 
Issue 9, July 2005, Pages  1941-1948 
The solubility of sodium loxoprofen was determined over a range of 
temperatures from 15.2°C to 39.7°C by two methods: analyses of samples from 
equilibrated solutions and a recently developed procedure utilizing a focused-beam 
reflectance method (FBRM). 
 
Hui Cao et al; Preparation a novel pH-sensitive blend hydrogel based on 
polyaspartic acid and ethylcellulose for controlled release of loxoprofen 
sodium;Journal of Applied Polymer Science,  Mar 2009 
Hydrogels based on pH-sensitive polymers are of great interest as potential 
biomaterials for the controlled delivery of drug molecules. In this study, a novel, pH-
sensitive hydrogel was synthesized by poly(aspartic acid) (PASP) crosslinked with 
1,6-hexanediamine and reinforced with ethylcellulose (EC). 
 
Piera Di Martino et al; A new tetrahydrated form of sodium loxoprofen; Journal 
of Pharmaceutical Sciences, Volume 96, Issue 1, Sep 2006, Pages  156-157. 
The anhydrous sodium loxoprofen (ASN) can form several hydrated phases if 
maintained at different relative humidities (RH). The water uptake can promote 
crystallographic modifications, according to the amount of water. In a previous work, 
the authors showed that a dihydrated form could be obtained either by crystallization 
in water or by exposure of the anhydrous form to a RH of 55%. In the present work, 
the authors report about the formation and characterization of a new tetrahydrated 
form, obtained by exposing the ASN to RH  75%. All the hydrated compounds 
were characterized by the combined use of several spectroscopic, thermal, and 
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crystallographic techniques. The thermal stability of both the dihydrated and 
tetrahydrated compounds was also tested. 
 
Terry M. Phillips et al; Measurement of loxoprofen in human plasma by chip-
based immunoaffinity capillary electrophoresis; Biomedical Chromatography, 
Volume 20, Issue 6-7, Jun 2006,Pages 662 – 667 
 An electrokinetic immunoassay performed in a chip-based capillary 
electrophoresis system is described for the rapid measurement of loxoprofen in human 
plasma. The system employs a fluorescently labeled antibody to capture and detect 
the analyte of interest within a 5 min total assay time with an LOD of 0.025 µg/mL 
and a saturation level of 450 µg/mL. The system compared well with a conventional 
HPLC technique but was found to be much faster. Application of the electrokinetic 
assay to the study of patients with allergy to loxoprofen demonstrated increased 
concentrations of the drug extending past the predicted elimination half-life. The 
portability of the system and its ability to process up to 18 samples per hour makes it 
suitable for use in emergency room situations. 
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AIM AND OBJECTIVE  
 
AIM: 
 The main aim of the study to formulate and evaluate loxoprofen sodium 
tablets. 
 
 
OBJECTIVE:  
 The objective of the present study is to develop a pharmaceutically stable and 
robust formulation of Loxoprofen sodium tablets comparable with innovator. 
  To   achieve this goal various prototype trials are taken & evaluated with 
respect to various quality parameters. 
 The formulation shall be finalized by comparing the in - vitro dissolution 
profile with that of the innovator in various pH
 
media. 
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                                                 PLAN OF WORK 
 
 
 
 
 
 
 
  
RAW MATERIAL EVALUATION 
PREFORMULATION 
DRUG EXCIPIENT COMPATABILITY STUDY 
(Justification given for the same)  
PROTOTYPE FORMULATION 
(Lab Scale development) 
T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 
 
PHYSICAL CHARACTERISTICS OF BLEND 
 LOD, Bulk Density, moisture content and 
Sieve analysis. 
COMPRESSION AND COATING 
Above mentioned physical parameters and 
Chemical Evaluation viz; Assay, Related 
substances and Dissolution. 
STABILITY STUDIES 
Physical and chemical evaluation during 
stability studies 
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DRUG PROFILE 
                                        
Loxoprofen Sodium
7,8 
Structure: 
                                                 
                 
Chemical Formula    : C15H17NaO3,  
Description  : Loxoprofen sodium is an odorless crystalline powder, white to 
                                      creamy in color.                                           
Solubility            : It is soluble in methanol and water. 
Molecular Weight    :  268.28 
Category              : A member of the aryl acetic acid group of non-steroidal anti-             
inflammatory drugs (NSAIDs). 
Storage                     : Store at controlled room temperature, 20° - 25° C (68° - 77° F). 
Dispense in a well-closed container. 
Actions: 
         Loxoprofen is a non-steroidal anti-inflammatory drug (NSAID), with analgesic 
and antipyretic properties. As with other NSAIDs, its mode of action is not fully 
understood; however, its ability to inhibit prostaglandin synthesis may be involved in 
anti-inflammatory effect.                                                                           
 
Pharmacokinetics:
7,8,11
 
 Although loxoprofen itself is well absorbed, the sodium salt form is more 
rapidly absorbed resulting in higher peak plasma levels for a given dose. After oral 
administration, plasma levels of loxoprofen are detected within 30 minutes of dosing, 
with peak plasma levels occurring approximately 5 hours after dosing. The observed 
terminal elimination half-life of loxoprofen from loxoprofen sodium tablets is 
approximately 15 hours. Steady state levels of loxoprofen are achieved in 3 days and 
the degree of loxoprofen accumulation in the blood is consistent with this. 
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Absorption 
 Loxoprofen itself is rapidly and completely absorbed from the GI tract with an 
in vivo bioavailability of 95%. Based on the pharmacokinetic profile, the absorption 
phase of   tablets occurs in the first 4-6 hours after administration. . In common with 
conventional loxoprofen and loxoprofen sodium formulations, food causes a slight 
decrease in the rate of loxoprofen absorption. 
 
Distribution 
 Loxoprofen has a volume of distribution of 0.16 L/kg. At therapeutic levels, 
loxoprofen is greater than 99% albumin-bound. At doses of loxoprofen greater than 
500 mg/day, there is a less than proportional increase in plasma levels due to an 
increase in clearance caused by saturation of plasma protein binding at higher doses. 
However the concentration of unbound loxoprofen continues to increase 
proportionally to dose 
 
Metabolism 
           Loxoprofen is extensively metabolized to 6-0-desmethyl loxoprofen and both 
parent and metabolites do not induce metabolizing enzymes. 
 
Elimination 
 The elimination half-life of Loxoprofen is approximately 15 hours. Steady 
state conditions are attained after 2-3 doses of Loxoprofen Tablets. Most of the drug 
is excreted in the urine, primarily as unchanged loxoprofen (less than 1%), 6-0-
desmethyl loxoprofen (less than 1%) and their glucuronide or other conjugates (66-
92%). A small amount (< 5%) of the drug is excreted in the feces. The rate of 
excretion has been found to coincide closely with the rate of clearance from the 
plasma. In patients with renal failure, metabolites may accumulate. 
Indication: 
 Tablets are indicated for the treatment of, 
  Rheumatoid arthritis, 
  Osteoarthritis,  
 Ankylosing spondylitis,  
 Tendinitis,  
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 Bursitis  
 Acute gout.  
 It is also indicated in the relief of mild to moderate pain and the treatment of 
primary dysmenorrhea. Rheumatoid Arthritis, Osteoarthritis, and Ankylosing 
Spondylitis 
 
Drug Interactions: 
ACE-inhibitors 
Reports suggest that NSAIDs may diminish the anti-hypertensive effect of ACE-
inhibitors. This interaction should be given consideration in patients taking NSAIDs 
concomitantly with ACE-inhibitors. 
Aspirin 
 When Loxoprofen is administered with aspirin, its protein binding is reduced, 
although the clearance of free Loxoprofen is not altered. The clinical significance of 
this interaction is not known; however, as with other NSAIDs, concomitant 
administration of loxoprofen and aspirin is not generally recommended because of the 
potential of increased adverse effects. 
Diuretics 
 Clinical studies, as well as post-marketing observations, have shown that 
Loxoprofen can reduce the natriuretic effect of furosemide and thiazides in some 
patients. This response has been attributed to inhibition of renal prostaglandin 
synthesis. During concomitant therapy with NSAIDs, the patient should be observed 
closely for signs of renal failure, as well as to assure diuretic efficacy. 
Lithium 
 NSAIDs have produced an elevation of plasma lithium levels and a reduction 
in renal lithium clearance. The mean minimum lithium concentration increased 15% 
and the renal clearance was decreased by approximately 20%. These effects have 
been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Thus, 
when NSAIDs and lithium are administered concurrently, subjects should be observed 
carefully for signs of lithium toxicity. 
Methotrexate 
 NSAIDs have been reported to competitively inhibit methotrexate 
accumulation in rabbit kidney slices. This may indicate that they could enhance the 
Chapter 5                                                                                                            DRUG PROFILE 
Dept of Pharmaceutics                                   J.K.K.Nattraja College of Pharmacy.  23 
 
toxicity of methotrexate. Caution should be used when NSAIDs are administered 
concomitantly with methotrexate. 
 
Warfarin 
 The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that 
users of both drugs together have a risk of serious GI bleeding higher than users of 
either drug alone. 
 
Adverse Effects: 
 The most frequent adverse events are headache, followed by dyspepsia, and 
flu syndrome   
Others include: 
 Body as a Whole- Pain (back), pain, infection, fever, injury (accident), 
asthenia, pain chest, headache (15%), flu syndrome (10%). 
 Gastrointestinal- Nausea, diarrhea, constipation, abdominal pain, flatulence, 
gastritis, vomiting, dysphagia, dyspepsia (14%), heartburn, stomatitis. 
 Hematologic- Anemia, ecchymosis. 
 Respiratory- Pharyngitis, rhinitis, sinusitis, bronchitis, cough increased. 
 Renal- Urinary tract infection, cystitis. 
 Dermatologic- Skin rash, skin eruptions, ecchymoses, purpura. 
 Metabolic and Nutrition- Peripheral edema, hyperglycemia. 
 Central Nervous System-Dizziness, paresthesia, insomnia, drowsiness, 
lightheadedness.  
 Cardiovascular- Hypertension, edema, dyspnea, palpitations. 
 Musculoskeletal- Cramps (leg), myalgia, arthralgia, joint disorder, tendon 
disorder. 
 Special Senses- Tinnitus, hearing disturbances, visual disturbances. 
 General- Thirst. 
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CHARACTERIZATION OF INNOVATOR PRODUCT 
Description of innovator product: 
Product Name      :  Aleve 
Expiry Date          :  May    2010 
Distributed by      :  Bayer Healthcare LLC, USA 
 
Composition         : 
       Table-1: Composition Of Innovator Product                   
S.no     Excipients in Aleve 
     
    1 
 
    2 
 
    3 
 
   4 
 
   5 
 
   6 
 
   7 
 
   8 
 
   9 
 
  10 
  
 FD&C Blue #2 
 
 Hypromellose  
 
 Magnesium stearate  
 
 Micro Crystalline Cellulose  
 
 Povidone 
 
 Poly ethylene glycol 
 
 Pregelatinised maize starch 
 
Maize Starch  
 
 Sodium Starch Glycolate  
 
 Stearic acid  
 
 
Packaging:  
                                                                            
     Strength                Packs available 
      220mg  HDPE container (CRC),100CC 
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Physicochemical Evaluation of Aleve 220 tablets: 
 Description                 :  Blue Colored, Oval shaped, biconvex film coated tablet,  
                                        debossed  with ‘ALEVE’ on one side and other side. 
 Avg. Weight  :  300.0mg 
Strength                  :  220mg 
Length                     : 12.0mm 
Width                       : 7.4mm 
Thickness                : 4.50-5.00mm 
Hardness                 : 5.0-12.0kp 
DT                            : 12.30min 
Table -2 : Dissolution Data 
    Time (min) % Drug Release 
5 
10 
15 
30 
45 
60 
37.90 
69.60 
86.90 
100.80 
101.60 
102.80 
                     
 Fig -1 : Invitro Dissolution Profile of Loxoprofen Sodium  
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MATERIALS AND EQUIPMENTS USED 
 
Materials Used 
The following were the list of excipients selected for the formulation, but the  
finalized list of excipients were based on the innovator product:  
 
Table -3 :  List Of Excipients Selected For The Formulation, 
  S.No Ingredients used Category 
1 Loxoprofen Sodium Active  
2 
 Maize Starch  
 
Binder/diluents 
3 Pregelatinized Maize Starch  Binder/diluents 
4 Micro crystalline cellulose (MCC) Diluent 
5 Sodium Starch Glycolate(SSG) 
Disintegrant 
 
6 
Povidone K-30 
 
Binder 
7 
Stearic acid 
 
Lubricant 
8 
Purified Water 
 
Vehicle 
9 
 Aquarius BP 17066 
 
Coating Material 
10 Purified water Solvent 
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Microcrystalline Cellulose
9 
 
 
Synonyms Celex, Avicel PH, crystalline cellulose  
Chemical Name  Cellulose 
 Empirical Formula (C6H10O5)n 
Functional Category Adsorbent, diluent, disintegrant 
Description 
It is purified, partially depolarized cellulose that occurs as 
white, odorless, crystalline powder composed of porous 
particles. 
Uses of MCC   
Use                                                 concentration (%) 
Adsorbent                                           20-90 
Antiadherent                                         5-20 
Capsule binder/diluent                        20-90 
Tablet disintegrant                                5-15 
Tablet binder/diluent                           20-90 
Melting Point 260-270
0
 C 
Moisture Content Less than 5% 
Solubility 
Slightly soluble in 5% w/v hydroxide solution; practically 
soluble in water, dilute acids, and most organic solvents. 
stability and storage 
It is a stable through hygroscopic material. Bulk material 
should be stored in a well – closed container in a cool, dry 
place.  
Incompatibilities Incompatible with strong oxidizing agents 
Safety Non toxic and non irritant material 
Precautions  
It may be irritant to the eyes. So gloves, eye protection, 
and dust mask are recommended. 
Regulatory status  GRAS listed. 
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Sodium Starch Glycolate
9 
 
Synonyms Carboxy methyl starch, sodium salt, explotab, primojel. 
Chemical Name  Sodium carboxymethyl starch 
Empirical Formula 
The USPNF 20 states that sodium starch glycolate is the 
sodium salt of a carboxymethyl ether of starch. 
Concentration use of 
sodium starch 
glycolate 
2-8% 
Functional Category Tablet and capsule disintegrant. 
Description 
Sodium starch glycolate is a white to off-white, odorless, 
tasteless, free-flowing powder. It consists of oval or 
spherical granules, 30-100 um in diameter, with some less-
spherical granules ranging from 10-35 um in diameter. 
Melting Point Does not melt, but chars at approximately 200° C 
Swelling Capacity 
In water, sodium starch glycolate swells to up 300 times its 
volume. 
Solubility 
Sparingly soluble in ethanol (95%), practically insoluble in 
water. At a concentration of 2 % w/v sodium starch 
glycolate disperses in cold water and settles in the form of 
a highly hydrated layer. 
Incompatibilities 
Sodium starch glycolate is incompatible with ascorbic 
acid. 
Safety 
Nontoxic and nonirritant material. However, oral ingestion 
of large quantities may be harmful. 
Related substances Pregelatinized starch, starch. 
Stability and Storage 
Conditions 
 Tablets prepared with Sodium starch glycolate have good 
storage properties. Sodium starch glycolate is stable and 
should be stored in a well-closed container in order to 
protect it from wide variations of humidity and 
temperature, which may cause caking . 
The physical properties of Sodium starch glycolate remain 
unchanged for up to 4 years if it is stored at moderate 
temperatures and humidity. 
Regulatory status 
Including in the FDA Ingredients Guide (oral capsules and 
tablets). 
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Povidone K-30
9 
 
Synonyms Kollidone, pvp, plasdone 
Chemical Name  1-Ethyl-2-pyrrolidinone homopolymer 
Empirical Formula (C6H9NO)n 
Functional Category 
Disintegrant, dissolution aid, suspending agent, tablet 
binder. 
Uses of Povidone 
Use                                                 concentration (%) 
Carrier for drugs                                     10-25 
Dispersing agent                                     up to 5 
Eye drops                                                2-10 
Suspending agent                                    upto5    
Tablet binder, tablet diluent,                    
 or coating agent                                       0.5-5 
Description 
It occurs as a fine, white to creamy – white colored, 
odorless or almost odorless, hygroscopic powder. 
Melting Point Softens at 150°C 
Moisture Content It is very hygroscopic  
Solubility 
Freely Soluble In Acids, Chloroform, Ethanol, ketone      
And Water; practically insoluble in ether, hydrocarbons, 
and mineral oil. 
Stability and Storage 
Conditions  
Povidone darkens to some extent on heating at 150°C, with 
a reduction in aqueous solubility. It is stable to a short 
cycle of heat exposure around 110-130° C, steam 
sterilization of an aqueous solution does not alter its 
properties. 
Incompatibilities 
Povidone is compatible in solution with a wide range of 
inorganic salts, natural and synthetic resins, and other 
chemicals. It forms molecular adducts in solution with 
sulfathiazole, sodium salicylate, salicylic acid, 
Phenobarbital, tannin, and other compounds. The efficacy 
of some preservatives, e.g. Thimersol, may be adversely 
affected by the formation of complexes with povidone. 
Safety 
It is nontoxic, nonirritant and it is not absorbed from the GI 
or mucous membranes. 
Related substances Crospovidone 
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Stearic acid :
9 
 
Synonyms Crodacid,Hystreme,Pristerene 
Chemical Name  Octadecanoic acid  
Empirical Formula C18H36O2 
molecular weight 284.47 
Functional Category 
Emlsifying agent,solublizing agent,tablet & capsule 
lubricant.  
Concentration Used 
Ointment &creams-1-20% 
Tablet lubricant-1-3% 
Description 
 It is a hard, white or yellow colored,somewhat 
glossy,crystalline solid or a white or yellowish white 
powder.It has a slight odor & taste suggesting tallow.  
Melting Point ≥54oC 
Moisture Content - 
Solubility 
Freely soluble in benzene,carbon tetrachloride,chloroform 
& ether;soluble in ethanol,PEG & hexane,practically 
insoluble in water.  
Incompatibilities 
It is incompatible with most metal hydroxides & may be 
incompatible with oxidizing agents. 
Safety Nontoxic 
Regulatatory  
acceptance 
GRAS listed 
Related substances Calcium stearate, Magnesium stearate, zinc stearate 
Stability and Storage 
Conditions 
Magnesium stearate is stable and should be stored in a 
well-closed container in a cool, dry place. 
Stability and Storage 
Conditions 
 It is a stable material,an antioxidant may be added. 
Regulatory status 
Including in the FDA Ingredients Guide (oral capsules and 
tablets). 
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Pregelatinised Maize Starch
9 
: 
 
 
Synonyms 
Compressible Starch, Lycatab C, Lycatab PGS, Mrigel, 
Starch 1500 G, Pharma Gel. 
Chemical Name Pregelatinized Starch 
Empirical Formula C6H10O5 
Molecular Weight 300-1000 
Functional Category 
Tablet and capsule diluent; tablet and disintegrant; tablet 
binder. 
Uses of pregelatinized 
starch  
Use                                                 concentration (%) 
Diluent(hard gelatin capsule)                5-75                       
Tablet binder (direct compression)       5-20                              
Tablet binder (wet granulation)             5-10                                   
Tablet disintegrant                                 5-10    
Description 
Pregelatinized Starch occurs as a moderately coarse to 
fine, white to off-white colored powder. It is odorless and 
has a slight characteristic taste. 
Examination of Pregelatinized Starch as slurry in cold 
water, under a polarizing microscopic, reveals no 
significant ungelatinized granules, no “maltese crosses” 
characteristic of the starch birefringence pattern. 
Moisture Content Pregelatinized Starch is hygroscopic. 
Solubility 
Practically insoluble in organic solvents. Slightly soluble 
in cold water, depending upon the degree of 
pregelatinization. Pastes can be prepared by sifting the 
Pregelatinized Starch into stirred, cold water. Cold water-
soluble matter for partially Pregelatinized Starch is 10-
20%. 
Incompatibilities - 
Safety 
Pregelatinized Starch and starch are widely used in oral 
solid dosage formulations. Pregelatinized Starch is 
generally regarded as a nontoxic and nonirritant excipient. 
However, oral consumption of massive amounts of 
Pregelatinized Starch may be harmful. 
Related substances Starch, sterilizable maize. 
Stability and Storage 
Conditions 
Pregelatinized Starch is a stable but hygroscopic material, 
which should be stored in a well-closed container in a 
cool, dry place. 
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Equipments Used: 
 
S.No. 
 
Name of Instrument Manufacturing Company 
1  Automatic tablet dissolution apparatus USP I Pharma Test 
2  Electronic thickness measurement apparatus Mitutoyos 
3  Friability tester USP 23 Electro Lab 
4  Tablet hardness tester Pharma Test 
5  
Electronic LOD measurement apparatus 
(Halogen Moisture Analyzer) 
Mettler Toledo 
6  Tap Density Apparatus USP Electro lab,  
7  Electronic weighing balance, 150 Kg Mettler Toledo, 
8  Electronic weighing balance, 6 Kg Mettler Toledo 
9  Electronic weighing balance, 300 Gms Mettler Toledo,  
10  Lab stirrer 8 Liters Eltech 
11  Single Deck Sifter SWECO 
12  Octagonal Blender 10 Liters Saan 
13  Tablet compression machine 12 station RIMEK – minipress 
14  Fluid Bed Processor (FBP) FBE – 5 P+am Glatt 
15  Tablet Coating Machine (Neocota – 5 kg) Neomachines 
16  Moisture Content ( KF Titrino ) Metrohm 
17  UV – Spectrometer Shimadzu 
18  HPLC   Waters – alliance 
19  Disintegration Test Apparatus Electro lab,  
20  Rapid Mixer Granulator Sainath Boilers & Pneumatics 
21  Electronic Sieve shaker SWECO 
22  pH meter Polmon 
 
 
 
Chapter 6                                                                                                         METHODOLGY 
Dept of Pharmaceutics                                   J.K.K.Nattraja College of Pharmacy   33 
 
EXPERIMENTAL WORK 
PREFORMULATION STUDIES
6,10 
Preformulation testing is an investigation of physical and chemical properties of a 
drug substance alone and when combined with excipients. It is the first step in the 
rational development of dosage forms. 
 
Description and solubility: 
Loxoprofen Sodium is white to off white powder, practically insoluble in water and 
melt at 105ºc. 
Determination of bulk density and tapped density 
Density is defined, as the ratio of mass to the volume. The density of a powder 
sample is usually referred to as bulk density, and the volume includes both the 
particulate volume and the pore volume. The bulk density will vary depending on the 
packing of powder, several values can be quoted.  
 
Bulk density is when the volume of the powder is at maximum, caused by aeration, 
just prior to complete breakup of the bulk. Tapped density is the maximum bulk 
density that can be achieved without deformation of the particles. In practice, it is 
generally unrealistic to attain this theoretical tapped density, and a lower value 
obtained after tapping the sample in a standard manner is used. 
 
The bulk density, and tapped density were calculated using the following formulas: 
                                           
                                 
 
 
 
                                            
                               Where, 
                                           W = weight of the powder 
                                           VO = intial volume 
                                           VF = final volume 
 
Bulk density     (B.D) = W / Vo 
 
Tapped density (T.D) = W / Vf 
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Compressibility Index: 
 The compressability index is indirectly related to relative flow rate, cohesiness 
and particle size of the powder. The compressability index of material can be 
estimated from the tapped and bulk density of power.      
%Compressability index = [(T.D – B.D) / T.D] 100 
Where T.D and B.D are bulk density and tap density respectively.    
 
CARR’S INDEX: 
 
      COMPRESSIBILITY                                                  FLOW DESCRIPTION 
 5-15       Excellent 
 12-1 Good 
 18-21 Fair 
 23-28        Poor 
 28-35       Moderately Poor 
 35-38 Very poor 
 >40       extremely poor 
 
 
HAUSNERS RATIO: 
It indicates the flow properties of a powder; it is measured by ratio of tapped 
density to bulk density      
          Hausner’s Ratio = TappedDensity                                                                                                                                                                                                                                                                      
.                                      Bulk Density 
                    
                     Hausners ratio          Type of flow 
                    Less than 1.25                    Good flow 
 1.25-1.5                                                                 Moderate flow 
                     More than 1.5        Poor flow 
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SIEVE ANALYSIS: 
The main aim of sieve analysis is to determine the different sizes of particles present 
in the mixture. A series of standard sieve were stacked one above the other so that 
sieves with larger pore size (less sieve number) occupy top position followed by 
sieves of decreasing pore size (larger sieve number towards the bottom) 
 
Procedure: A series of sieves were arranged in the order of their decreasing pore 
diameter (increasing sieve number) i.e. sieve number 40, 60, 80, 100, 120, 200, 325# 
and pan. 100 grams of drug was weighed accurately and transferred to sieve 40 which 
were kept on top. The sieves were shaken for about 5-10 minutes. Then the drug 
retained on each sieve was taken, weighed separately and amount retained was 
expressed in terms of cumulative percentage retained. 
 
             Particle size % cum. Retention 
40# 6.0 
60# 11.2 
80# 14.0 
100# 15.2 
200# 18.0 
325# 22.8 
Pan 77.2 
 
DRUG EXCIPIENT COMPATIBILITY STUDIES 
Compatibility studies are carried out to study the possible interactions between 
Loxoprofen Sodium and other inactive ingredients. 
 
Procedure: The compatibility studies were carried out by taking a mixture of drug 
and excipients at the ratio in which they are expected to be present in the innovator 
product. A part of mixture can be exposure to different storage conditions like 
40
o
C/75% RH, 30
o
C/60%RH and control samples were to be kept at 2-8
o
C. They 
were tested with respect to their   physical and chemical aspects. 
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Table-4: Drug Excipient Compatibility studies 
S.No      Condition          Samples packed  in  Samples obtained at 
    1 
 
     
     2 
     
 
     3 
Accelerated  
40
o
C/75% RH 
 
Intermediate  
30
o
C/60%RH  
 
Refrigeration   2-8
o
C 
3 Double polythene bags 
 
 
2 glass vessels 
 
 
1 Double polythene bag + 
1 glass vessel 
        1M, 2M, 3M 
 
       
15 days, 30 days 
 
        
 
                3M 
 
 
Table-5: 
Sr. 
No 
Name of the Excipient Category 
Compatibility status with 
LOXOPROFEN SODUM 
1 
Microcrystalline 
cellulose (MCC) 
Diluent Compatible  
2 
Maize Starch  
 
Diluent Compatible 
3 
Pregelatinized Maize 
Starch 
Diluent Compatible 
3 
Povidone K-30 
 
Binder Compatible 
    4 
Sodium Starch    
Glycolate(SSG) 
Disintegrant 
 
Compatible 
 
5 
Stearic acid 
 
Lubricant Compatible 
6 
Purified Water 
 
Vehicle Compatible 
7 Aquarious BP 17066 Coating material Compatible 
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DEVLOPMENTAL DESIGN OF LOXOPROFEN SODIUM TABLETS  
 
Process Flow Chart for Manufacturing of Loxoprofen Sodium Tablets: 
                            
                                                  
 
 
 
  
 
                                                         
 
 
 
 
 
   
 
 
   
 
    
 
 
  
 
    
 
 
 
 
 
 
LOADING OF MATERIALS 
INTO RMG 
       GRANULATION   
        
BINDER 
ADDITION 
DRYING 
 
Sample for LOD 
SIZING 
       MILLING (if felt 
necessary)         
Dry milling of 
sieve tops 
            BLENDING Sample for Complete 
Analysis 
       COMPRESSION 
 
           COATING 
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MANUFACTURING PROCEDURE: 
 
Granulation: 
 
Dry Mixing: 
Load Loxoprofen sodium into RMG along with diluent and mixed for 5 min at slow 
mixer speed. 
Preparation of Binder Solution: 
Dissolve the binder in hot Purified water. Stir with SS paddle till complete Povidone 
goes into solution. 
Wet Granulation: 
Add binder into RMG while mixing at slow mixer speed. Add extra water till required 
consistency of mass is obtained. 
  Drying: 
Start the FBP in manual mode & set process parameters as given below. Dry the wet 
granules at 105
0
C till a LOD of 0.5%w/w – 1.0 %w/w is achieved. (Actual limit 
established during the trials). Unload the granules. Record all the parameters of fluid 
bed processor from the process record sheet. 
Sifting: Sift the dried granules through # 18 mesh. 
Blending and Lubrication:   
Load the sifted granules into Octagonal blender, Lubricant is added into blender by 
sifting it in 40 mesh and blended for 5 min at 8 rpm. 
COMPRESSION: 
Compress the blend into tablets using 12.0 × 7.3 mm punches and suitable dies with a 
tablet weight of 300.0 mg. 
 COATING: 
Coat the tablets to get 2.5 % buildup by using 15% coating solution. Maintain the 
following parameters during coating: 
Inlet temperature: 50-60
0
c 
Bed temperature: 45-50
0
c 
Spray rate-6gm/min. 
Spray pump rpm-6 
Automization air pressure-1.8 bar 
Gun to bed distance-11.5cm 
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FORMULATION DEVEL0PMENT: 
Trial: 1 
I.  Objective: To manufacture Loxoprofen Sodium Tablets: 
II.  Batch size: 2.0 kg. 
III.  Table-6: Formula 
S.No Ingredients % Comp Qty/Batch(kg) 
 Dry mix   
1 Loxoprofen Sodium  73.33 1.466 
2 Maize starch 20.57 0.412 
3 Pregelatinised starch 3.6 0.072 
4 Sodium Starch 
Glycolate 
1.2 0.024 
 Binder   
5 Povidone k-30 0.5 0.010 
6 Purified water QS 900 
 Lubricants   
7 Stearic acid 0.8 
 
0.016 
Total  100.0 2.0 
 
IV. Procedure: 
          The granulation and compression procedure is same as mentioned earlier. 
 
V. Observation/Conclusion:  
           Granules were not found. 
 
VI. Further Plan of action:  
         Another batch is planned by PVP-K 30(0.7%), Maize starch (20.37%),     
         PGMS(3.2%) SSG(1.6%). 
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Trial: 2 
I. Objective: To manufacture Loxoprofen Sodium Tablets by taken  
                   PVP-K 30 (0.7). 
II. Batch size: 2.0 kg. 
III.  Table-7: Formula: 
 
 
IV.  Procedure:  
                  The granulation and compression procedure is same as  mentioned earlier. 
  
V.       Observation/Conclusion:  
                    Poor flow was observed, compression was not done. 
 
VI. Further plan of action: 
                  Another batch is planned by taking Maize starch (21.37%), PGMS (2%),   
                  SSG (2%) 
 
 
 
 
 
S.No Ingredients % Comp Qty/Batch(gm) 
 Dry mix   
1 Loxoprofen Sodium 73.33 1.466 
2        Maize starch 20.37 0.408 
3 Pregelatinised starch 3.2 0.064 
4 Sodium Starch 
Glycolate 
1.6 0.032 
 Binder   
5 PVP K-30 0.7 0.014 
6 Purified water QS 900 
 Lubricants   
7 Stearic acid        0.8 0.016 
Total 100.0 2.0 
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Trial: 3 
I. Objective: To prepare Loxoprofen Sodium Tablets by taking Maize starch   
                        (21.37%), PGMS (2%), SSG (2%) 
 
II. Batch size: 2.0 kg. 
III. Table-8: Formula: 
 
S.No Ingredients % Comp Qty/Batch(gm) 
 Dry mix   
1 Loxoprofen Sodium 73.33 1.466 
2 Maize starch 21.37 0.428 
3 Pregelatinised starch 2.0 0.040 
4 Sodium starch 
glycolate 
2.0 0.040 
 Binder   
5 Povidone k-30 0.5 0.010 
6 Purified water QS 900 
 Lubricants   
7 Stearic acid       0.8 0.016 
Total 100 2.0 
 
IV. Procedure: 
                   The granulation and compression procedure was same as mentioned 
earlier. 
 
V. Observation/Conclusion:   
                    Poor flow of granules was found and Rat holding was observed during    
                    compression. 
 
VI.       Further plan of action:   
                  Another batch is planned by taking Micro crystalline cellulose (21.17%),  
                  PVP K30 (0.7%) 
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Trial: 4 
I. Objective: To prepare Loxoprofen Sodium Tablets by taking  
                          Micro crystalline cellulose (21.17%), PVP K 30 (0.7%). 
II. Batch size: 2.0 kg. 
III. Table-9: Formula: 
 
S.No Ingredients % Comp Qty/Batch(gm) 
 Dry mix   
1 Loxoprofen Sodium 73.33 1.466 
2 Micro crystalline 
sodium 
21.17 0.425 
3 Pregelatinised starch 2.0 0.040 
4 Sodium starch glycolate 2.0 0.040 
 Binder   
5 Povidone k-30 0.7 0.014 
6 Purified water QS 900 
 Lubricants   
7 Stearic acid 0.8 0.016 
Total 100.0 2.0 
 
 
IV. Procedure:  
 The granulation and compression procedure is same as  mentioned earlier. 
 
V. Observation/Conclusion:  
Better granules were observed and DT is not matching with that of 
innovater. 
 
VI. Further plan of action:  
Another batch is planned by taking Micro crystalline sodium (10.00%), 
Maize starch (11.17%). 
 
 
Chapter 6                                                                                                         METHODOLGY 
Dept of Pharmaceutics                                   J.K.K.Nattraja College of Pharmacy   43 
 
Trial: 5 
I. Objective: To prepare Loxoprofen Sodium tablets  by taking  
              Micro crystalline sodium  (10.00%), Maize starch (11.17%). 
II. Batch size: 2.0 kg. 
     III. Table-10: Formulation: 
S.No Ingredients % Comp Qty/Batch(kg) 
 Dry mix   
1 Loxoprofen sodium 73.33 1.466 
2 Micro crystalline 
sodium 
10.00 0.200 
3 Maize starch 11.17 0.224 
4 Pregelatinised starch 2.0 0.040 
5 Sodium starch 
glycolate 
2.0 0.040 
 Binder   
6 Povidone k-30 0.7 0.014 
7 Purified water QS 900 
 Lubricants   
8 Stearic acid 0.8 0.016 
Total 100.0 2.0 
 
IV. Procedure:  
The granulation and compression procedure is same as mentioned earlier. 
 
V. Observation/conclusion:  
Better granules were observed, but more Disintegration time . 
 
      VI.       Further plan of action:   
                  Another batch is planned by taking Maize starch (11.67%), Micro     
                  Crystalline Cellulose  (11.50%). 
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Trial: 6  
I. Objective: To prepare Loxoprofen sodium tablets  by taking     
                               Maize starch (11.67%), Micro crystalline Cellulose  (11.50%). 
     II. Batch size: 2.0 kg. 
    III. Formulation: 
           Table-11: 
 
 
IV. Procedure:  
The granulation and compression procedure is same as  mentioned earlier. 
 
V. Observation/conclusion: 
Disintegration time is matching with that of innovator but not the 
Dissolution profile. 
 
VI. Plan of action:  
Another batch is planned by taking MCC (11.0%), Maize starch (10.87%),  
PVP K30 (2%) 
 
 
S.No Ingredients % Comp Qty/Batch(kg) 
 Dry mix   
1 Loxoprofen sodium 73.33 1.466 
2 Micro crystalline 
cellulose 
11.50 0.230 
3 Maize starch 11.67 0.234 
4 Sodium starch  
glycolate 
2.0 0.040 
 Binder   
5 Povidone k-30 0.7 0.014 
6 Purified water QS 900 
 Lubricants   
8 Stearic acid 0.8 0.016 
Total 100.0 2.0 
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Trial: 7  
I. Objective: To manufacture Loxoprofen sodium tablets  by taking       
     MCC (11.0%), Maize starch (10.87%), PVP K30 (2%). 
II. Batch size: 2.0 kg. 
III. Formula: 
Table-12: 
S.No Ingredients % Comp Qty/Batch(kg) 
 Dry mix   
1 Loxoprofen sodium 73.33 1.466 
2 Micro crystalline 
cellulose 
11.0 0.220 
3 Maize starch 10.87 0.218 
4 Sodium starch 
glycolate 
2.0 0.040 
 Binder   
5 Povidone k-30 2.0 0.040 
6 Purified water QS 900 
 Lubricants   
7 Stearic acid 0.8 0.016 
Total 100.0 2.0 
 
  
IV. Procedure: 
The granulation and compression procedure is same as  mentioned earlier. 
 
V. Observation/Conclusion:  
Disintegration time is satisfactory but dissolution profile is not matching 
with reference sample. 
 
VI. Further plan of action: 
 Another batch is planned with Maize starch (8.87%), MCC (13.0%). 
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Trial: 8 
I. Objective: To prepare Loxoprofen sodium tablets with Maize starch   
                  (8.87%), MCC (13.0%). 
II. Batch size: 2.0 kg. 
III. Formulation: 
        Table-13: 
S.No Ingredients % Comp Qty/Batch(kg) 
 Dry mix   
1 Loxoprofen sodium 73.33 1.466 
2 Micro crystalline cellulose 13.0 0.260 
3 Maize starch 8.87 0.178 
4 Sodium starch glycolate 2.0 0.040 
 Binder   
5 Povidone k-30 2.0 0.040 
6 Purified water QS 900 
 Lubricants   
7 Stearic acid 0.8 0.016 
Total 100.0 2.0 
 
IV. Procedure: 
                   The granulation and compression procedure same as mentioned earlier. 
 
V. Observation/Conclusion:  
                   Disintegration time is satisfactory but dissolution profile is not matching 
                   with reference   sample. 
                      
VI.      Plan of action:  
                   Next batch planned with MCC (15%), Maize starch (6.87%). 
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Trial: 9 
I. Objective: To manufacture Loxoprofen sodium tablets with     
                          MCC (15%), Maize starch (6.87%). 
     II. Batch size: 2.0 kg. 
    III. Formulation: 
       Table-14: 
S.No Ingredients % Comp Qty/Batch(kg) 
 Dry mix   
1 Loxoprofen sodium 73.33 1.466 
2 Micro crystalline 
cellulose 
15.0 0.300 
3 Maize starch 6.87 0.138 
4 Sodium starch 
glycolate 
2.0 0.040 
 Binder   
5 Povidone k-30 2.0 0.040 
6 Purified water QS 900 
 Lubricants   
7 Stearic acid 0.8 0.016 
Total  100.0 2.0 
 
IV. Procedure:  
                  The granulation and compression procedure is same as  mentioned earlier. 
 
V. Observation: 
                    DT is satisfactory but percentage drug release is lower than that of    
                    innovater   sample. 
 
VI. Further plan of action:  
                    Next batch planned with MCC (14%), Maize starch (7.87%).  
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Trial: 10 
I. Objective: To manufacture Loxoprofen sodium tablets with  
                               MCC (14%),  Maize starch (7.87%).    
II. Batch size: 2.0 kg 
III. Formula:  
Table-15: 
S.No Ingredients % Comp Qty/Batch(kg) 
 Dry mix   
1 Loxoprofen sodium 73.33 1.466 
2 Micro crystalline 
cellulose 
14.0 0.280 
3 Maize starch 7.87 0.158 
4 Sodium starch 
glycolate 
2.0 0.040 
 Binder   
5 Povidone k-30 2.0 0.040 
6 Purified water QS 900 
 Lubricants   
7 Stearic acid 0.8 0.016 
Total  100.0 2.0 
 
IV. Procedure:  
                   The granulation and compression procedure is same as  mentioned earlier. 
 
V.      Observation/Conclusion: 
                  The granules produced have good flow property .As the Disintegration  
                   time and Dissolution profile were matching with innovater sample. 
 
VI.     Further plan of action:  
                 Two reproducibility batches are taken. 
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Trial: 11 and 12 
I. Objective:  To manufacture two reproducibility batches of Loxoprofen 
sodium tablets . 
    II. Batch size: 2.0 kg 
    III.  Formula: 
        Table-16: 
S.No Ingredients % Comp Qty/Batch(kg) 
 Dry mix   
1 Loxoprofen sodium 73.3 1.466 
2 Micro crystalline 
cellulose 
14.0 0.280 
3 Maize starch 7.87         0.158 
4 Sodium starch 
glycolate 
2.0 0.040 
 Binder   
5 Povidone k-30 2.0 0.040 
6 Purified water QS 900 
 Lubricants   
7 Stearic acid 0.8 0.016 
Total  100.0 2.0 
 
     IV. Procedure:  
The same granulation and compression procedure is followed. 
 
V. Observation/Conclusion: 
 Physical property of the granules are similar to that of the batch no.10 
and the Dissolution profile as well as the chemical properties of  the 
tablets are same  as that of batch no.10. 
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COMPARATIVE DATA OF VARIOUS FORMULATIONS: 
 Table-17: 
Trial 
Ingredient 
T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 
% COMPOSITION 
Loxoprofen 
Sodium 
73.33 73.33 73.33 73.33 73.33 73.33 73.33 73.33 73.33 73.33 
Maize starch 20.57 20.37 21.37 _ 11.17 11.67 11.0 13.0 15.0 14.0 
Pregelatinised 
maize starch 
3.60 3.20 2.0 2.0 2.0 _ _ _ _ _ 
Microcrystalline 
cellulose 
_ _ _ 21.17 10.00 11.50 11.0 13.0 15.0 14.0 
Sodium starch 
glycolate 
1.2 1.6 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 
PVP K-30 0.5 0.7 0.5 0.7 0.7 0.7 2.0 2.0 2.0 2.0 
Stearic acid 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 
TOTAL 100 
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RESULTS AND DISCUSSION:- 
 RESULTS: 
Compression Parameters:- 
   Table No.5 : Compress the blend into tablets by using 12.0 x 7.3 mm punches and suitable dies with a tablet weight of 300.3mg. 
TEST T1 T2 T3 T4 T5 T6 T7     T8 T9 T10 T11 T12 
Compression 
force-kg 
2500-
3000 
2400-
3000 
2300-
3000 
2400-
3100 
1700-
2200 
1800-
2300 
1700-
2100 
1700-
2100 
1700-
2200 
1700-
2300 
1800-
2200 
1800-
2200 
Hardness(Kp) 9-11 10-11 8-9 9-10 8-10 8-10 10-11 9-11 9-10 8-10 8-10 9-10 
Thickness-
mm 
4.50-
4.65 
4.65-
4.75 
4.60-
4.75 
4.65-
4.80 
4.80-
4.95 
4.80-
4.95 
4.75-
4.85 
4.70-
4.85 
4.80-
4.90 
4.85-
4.95 
4.80-
4.90 
4.85-
4.95 
Disintegratio
n time –min 
7.30 7.06 11.15 10.53 8.58 9.01 8.34 8.51 8.47 8.54 8.53 8.57 
Friability -
%w/w 
0.23 0.59 0.4 0.16 0.14 0.15 0.4 0.21 0.18 0.20 0.19 0.18 
Weight 
variation-mg  
295-
305 
300-
309 
307-
312 
299-
308 
298-
307 
300-
312 
305-
312 
302-
310 
305-
315 
299-
312 
300-
310 
298-
310 
 
 
COATED TABLET PARAMETERS: 
                   Table no.6: coated tablet parameters 
TEST T10 T11 T12 
Hardness-kp 9-11 8-11 10-12 
Thickness-mm 4.95 4.90 4.97 
Disintegration time –min 10.36 10.24 10.41 
Weight variation-mg  302-315 305-315 300-315 
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Table no.7: Dissolution data 
TIME 
(mins)  
 
CUMULATIVE PERCENT DRUG RELEASE (%) 
T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12 
0 0 0 0 0 0 0 0 0 0 
    0    0 0 
5 33.25 27.46 21.31 35.33 24.96 21.32 30.66 25.57 24.82 
31.2 32.8 32.3 
10 50.68 44.74 32.64 51.24 46.76 32.17 48.45 49.68 38.95 
53.6 55.2 46.8 
15 75.62 62.10 58.21 79.11 59.47 59.09 72.04 65.49 52.14 
71.2 62.8 72.8 
30 82.51 84.45 64.54 92.21 86.88 66.70 89.34 78.64 76.31 
100.4 99.8 101.7 
45 90.25 88.48 78.90 94.98 90.36 85.68 95.69 91.45 88.49 
102.3 102.5 102.8 
60 - 90.38 84.41 - 91.23 90.58 - 95.10 92.62 
103.5 103.2 103.5 
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EVALUATION: 
IN-VITRO RELEASE STUDIES: 
Innovator 
Dissolution medium:  Purified water 
Volume of medium   :  900ml 
Apparatus                  : USP-II (Paddle Type) apparatus. 
Speed (RPM)             :  50 
Temperature               :  37
o
C ±0.5
o
C 
Sampling points         :  5,10,15,30,45 & 60 min . 
Results: 
TIME (min) 5 10 15 30 45 60 
% Drug release  37.9 69.6 86.9 100.8 101.6 102.8 
 
 
Fig :2. Invitro Dissolution Profile of Loxoprofen Sodium Tablets  
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COMPARATIVE DISSOLUTION STUDIES: 
Dissolution was carried out at following conditions  
Dissolution medium: Purified water 
Volume of medium     :  900ml 
Apparatus                   : USP-II (Paddle  Type) apparatus. 
Speed (RPM)              :  50 
Temperature                :  37
o
C ±0.5
o
C 
Sampling points          : 5, 10, 15, 30, 45, and 60 minutes. 
 
Table:8 
Time Innovator T10 T11 T12 
0 0 0 0 0 
5 37.9 31.2 32.8 32.3 
10 69.6 53.6 55.2 46.8 
15 86.9 71.2 62.8 72.8 
30 100.8 100.4 99.8 101.7 
45 101.6 102.3 102.5 102.8 
60 102.8 103.5 103.2 103.5 
 
 
Fig :3. Comparitive Dissolution Profile of Loxoprofen Sodium Tablets 
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DISSOLUTION PROFILE COMPARISON USING f1 f2 FACTORS: 
A dissolution profile can characterize the product more precisely than a single point 
dissolution test. It helps to assure similarity in product performance and signals 
bioequivalance. The factor f1 is proportional to the average indifference between two 
profiles, where as factor f2 inversely proportional to the average squared indifference 
between two profiles. The factor f2 measures the closeness between two profiles, FDA  
has set a public standard of f2 value between 50-100 to indicate similarity between 
two profiles. 
  
 F1= ΣD(1/ Σt) x 100 
           F2=1÷ ΣD(1/ Σt) x 100 
Procedure: 
Take the mean dissolution values of the two profiles (test and innovator) which 
should be  
made under same test conditions and same time points. The time points taken as 5,10, 
15, 30, 45, 60 minutes. The following mathematical approach is made to compare the 
dissolution profile using two factors f1 and f2  .                          
Table no:9 
 
 
     N innovator(Rt) Test (Tt) D=(Rt-Tt)     (Rt-Tt)² F1= Σ D(1/ Σ t)100 
5 37.9 32.8 5.1 26.01  
   10 69.6 55.2 14.4 207.36  
  
f1=6.1 
   15 86.9 62.8 24.1 580.81 
   30 100.8 101.8 1.0 1.0 
   45 101.6 102.5 0.9 0.81 
   60 102.8 103.2 0.4 0.16  
       F1 = 6.1   n = 5    Σ Rt=499.6 ΣD=49.9 Σ (Rt-Tt)² 
= 816.15 
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Where:   
  f1=Dissimilarity factor,   f2=Similarity factor  
  Rt and Tt= Test and innovator cumulative percentage dissolution at selected time    
points.  
    N= Number of time point 
Results: 
 
Conclusion: The f1, f2 values of Loxoprofen Sodium Tablets determined as 6.1 and 
72.8, there are with in the limits and indicate similarity between two profiles.  
 
DISCUSSIONS  
 The assay of Loxoprofen Sodium in all trials lies within the limit and 
complies with the specifications. 
 The film coating process was also found to be smooth with no processing 
problems. 
 There is not much variation in the release of drug from the core as well as 
coated tablets indicating that the coating of tablets to obtain a 2.5% weight 
gain is found  
     to be sufficient to coat the tablets.       
 11th and 12th are planned for stability study. 
 
 
 
 
 
 
       Factors                    standards              obtained 
           f1                        0-15                    6.1 
           f2                      50-100                   72.8 
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STABILITY STUDIES 
Stability studies are an integral part of the drug development program & are one of 
the most important areas in the registration of pharma products. The purpose of 
stability testing is to provide evidence on how the quality of a drug substance or drug 
product varies with time under the influence of a variety of environmental factors 
such as temperature, humidity & light & enables recommended storage conditions, re-
test periods and self half lives to be established. Stability assessment starts with 
studies on the substance to determine degradation products degradation pathway. In 
these type of studies the product is analyzed at intervals for various parameters which 
may include assay of active ingredient, measurement of known degradation products, 
hardness, disintegration time, dissolution time, appearance etc. Loxoprofen sodium 
tablets USP 220mg were evaluated for accelerated stability studies at 40ºc/75% RH 
conditions. Stability details and results presented below 
  Storage conditions: 40ºC/75%RH 
Packs: HDPE containers 
Period: 1, 2 & 3 months 
Table no: 10 
 
S.NO 
 
                  
RESULT
→ 
TEST 
    ↓ 
STABILITY 
SPECIFICATIO
N 
40
0
C/75%RH 
INITIAL 30 DAYS 60 DAYS 90 DAYS 
 
1 
 
Descriptio
n 
Blue coloured 
oval shaped, 
biconvex film 
coated tablets, 
debossed with 
‘220’ on one side 
and plain on the 
other side. 
complies Complies 
 
Complies Complies 
2 
 
% Drug 
release 
NLT 80% of 
label claim in 
 45 min 
 
99.40 
 
99.57 
 
99.45 
 
99.51 
3 
 
 
Assay % 
w/w 
Between 90.0%-
110% of label 
claim. 
 
100.78 
 
100.24 
 
99.8 
 
99.97 
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SUMMARY AND CONCLUSION 
The main objective of the experimental work undertaken was to develop and evaluate 
the formulation of Loxoprofen sodium Tablets. The results of the study done are 
summarized as follows: 
1. The tablets manufactured also possessed acceptable parameters almost 
resembling the market sample. 
2. The coating process of the tablets was optimized with a good release of drug from 
the  coated tablets.  
 
  From the results it can be concluded that  Loxoprofen sodium Tablet was formulated 
and evaluated . Several trials have been taken to optimize and develop a robust 
formulation. Various processing problems were encountered during the formulation 
development and these were overcome with proper optimization of composition of 
formulation ingredients and processing conditions. The coated tablets were evaluated 
for the physical as well as chemical attributes and were found to be satisfactory in 
comparison to the market sample. Two reproducibility batches (T11 and T12) were 
taken for the finalized batch ie.T10 and were charged for stability studies at 
accelerated condition.  The stability study for 3 months shows that the formulation is 
stable enough at    40
0
C/75%RH. 
  
 
 
. 
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FUTURE PLAN 
 The formulation is a robust one and the performance is less likely to be 
affected by the various factors studied. An excellent in-vitro in-vivo correlation is 
expected as with respect to reference drug. The stability data is found to satisfactory 
and so the scale up as well as validation batches can be planned for further progress. 
 So it can be concluded that the Loxoprofen sodium tablets formulation is 
robust and stable. 
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